13 May 2021 - - Ireland-based ERS Genomics Ltd., which was formed to provide broad access to the foundational CRISPR/Cas9 intellectual property co-owned by Dr. Emmanuelle Charpentier, and US-based research reagent provider GenScript Biotech Corp. have inked a non-exclusive license agreement granting GenScript access to ERS Genomics' CRISPR/Cas9 patent portfolio, the companies said.

GenScript is a global biotechnology company providing life sciences research and application products and services, with a presence in the USA, Asia-Pacific, and Europe.

GenScript applies its proprietary oligonucleotide and gene synthesis technology to various fields from basic life sciences research to translational biomedical development, industrial synthetic products, and cell therapeutic solutions.

The ERS Genomics license will help further strengthen the GenScript CRISPR portfolio, from providing synthetic sgRNAs, gRNA plasmids, gRNA libraries, to cell line engineering services.

ERS Genomics holds an exclusive worldwide license from co-founder and recent Nobel prize winner Dr. Emmanuelle Charpentier to the foundational intellectual property covering CRISPR/Cas9 for use as a research platform.

Financial details of the agreement are not disclosed.